Healthcare

Chief Executive Officer Miranda Toledano said the quarter moved the company's team into late-stage clinical execution. The company said it is focused on a seamless trial launch and expects the first site to be activated in late 2026. The planned Phase 3 study is …

The company plans to host a conference call and webcast on November 13, 2026 at 9:00 AM Eastern Time to review the unaudited results. A live webcast will feature a set of presentation slides, which will be posted in the Investors section of the …

During the third quarter, Medicus entered into a co-development and license agreement with Pfizer for PF-08046031, a clinical-stage antibody-drug conjugate that targets melanotransferrin, also known as CD228. The company subsequently designated CD228V as its principal development priority, with an initial focus on establishing clinical …

PLATINUM-Truveta included 2,873 adults with MASH who started treatment with semaglutide 2.4 mg and 2,285 adults with MASH who started treatment with resmetirom. The adjusted outcomes were measured at three and six months. At three months, AST, a liver enzyme, fell by 6.7 units …

Lumos reported 265 sites across 29 states actively ordering FebriDx® as at 11 October 2026, versus 215 sites in 26 states on 15 September. Sites in evaluation rose to 485 from 405. Among the top 100 U.S. urgent care groups, five are live and …

Net operating outflow fell to A$19.1 million in the September quarter from A$38.9 million in the prior quarter, asResearch and Developmentcash use dropped to A$16.5 million with the TACTI-004 wind-down. Cash and term deposits closed at A$48.50 million. Management expects the balance to last …

Cynata launched a fully underwritten, pro-rata renounceable entitlement offer on 8 October 2026, offering three new shares for every eight held at A$0.01, each three shares carrying one free option. The price represented a 9.1% discount to the 7 October closing price. The offer …